Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

TEVAR-Twin: A Digital Twin Technology for Personalized Thoracic Aortic Care

Objective

Thoracic Endovascular Aortic Repair (TEVAR) is a minimally invasive treatment for thoracic aortic pathologies. Despite its widespread clinical adoption, preoperative planning is manual and experience-based, relying on measurements from computed tomography (CT) images. This simplified approach does not account for complex interactions between device and vessel. As a result, device selection is uncertain, contributing to complication and reintervention rates up to 30%, with significant clinical and economic consequences. TEVAR-Twin technology addresses this unmet need by transforming TEVAR planning from static geometric evaluation into a predictive and simulation-driven process. TEVAR-Twin will build a digital twin platform that reconstructs a 3D model of the patient’s aorta from CT imaging and virtually deploys commercially available stent-grafts using finite element simulations. The platform will introduce evidence-based decision support into routine TEVAR planning without disrupting existing clinical workflows enabling clinicians to compare multiple intervention strategies, providing both visualization of post-deployment configurations and clinically relevant metrics. The technology has been preliminarily validated on real patient cases, demonstrating high agreement (>90%) with post-operative outcomes. This project will advance the platform through structured technical verification, validation to generate QMS and CE-certification evidence. The final outcome will be a commercially ready and clinically validated medical device integrated into existing planning practice.
By creating the first clinically validated digital twin platform dedicated to TEVAR, AllStent positions itself in a new market segment in MedTech, allowing scalable impact across Europe and expansion to other endovascular applications. The technology has the potential to reduce complications, reinterventions and associated costs, while enhancing clinician confidence and patient safety.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC - HORIZON EIC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2026-AIC

See all projects funded under this call

Coordinator

ALLSTENT S.R.L.
Net EU contribution
€ 300 000,00
Address
VIA LUIGI CANONICA 25
20154 Milano
Italy
SME
Yes
Region
Nord-Ovest Lombardia Milano
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data